Evidence map›Paper›PMID 36508320›Full record

Trial reportDiabetes care2023

Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial.

Anna Obermayer, Norbert J Tripolt, Peter N Pferschy, Harald Kojzar, Faisal Aziz, Alexander Müller, Markus Schauer, Abderrahim Oulhaj, Felix Aberer, Caren Sourij and 6 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 8 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 8 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Time-Restricted Feeding With High-Fat Diet Slows Weight Gain and Reduces Renal Calcium Oxalate Crystal Formation Without Reducing Energy Intake.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  17. Article
  18. [Obesity and type 2 diabetes mellitus (Update 2026)].Wiener klinische Wochenschrift · 2026
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Anna ObermayerInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
Norbert J TripoltInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.ORCID 0000-0002-7566-2047
Peter N PferschyInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
Harald KojzarInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
Faisal AzizInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
Alexander MüllerInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
Markus SchauerDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Abderrahim OulhajCollege of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.
Felix AbererInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.ORCID 0000-0002-9947-1413
Caren SourijDivision of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Hansjörg HabischGottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.
Tobias MadlGottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.
Thomas PieberDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Barbara Obermayer-PietschDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Vanessa StadlbauerCBmed - Center for Biomarker Research in Medicine, Graz, Austria.
Harald SourijInterdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.ORCID 0000-0003-3510-9594
Medical University of Graz · ATKhalifa University of Science and Technology · AE

Funding

Austrian Science Fund FWF KLI 851
6 · The paper itself

Abstract

objectiveTo investigate the safety and feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. RESEARCH DESIGN AND

methodsForty-six people were randomized to an IF or control group. Dietary counseling and continuous glucose monitoring was provided. Coprimary end points were the change in HbA1c from baseline to 12 weeks and a composite end point (weight reduction ≥2%, insulin dose reduction ≥10%, and HbA1c reduction ≥3 mmol/mol).

resultsThe IF group showed a significant HbA1c reduction (-7.3 ± 12.0 mmol/mol) compared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012). The coprimary end point was achieved by 8 people in the IF and none in the control group (P < 0.001). No severe hypoglycemia occurred.

conclusionsIF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2InsulinIntermittent FastingBlood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinHumansHypoglycemic AgentsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin

Identifiers

PMID36508320
PMCPMC9887629
OpenAlexW4311178149

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.